In JoVE (1)
Other Publications (8)
- Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
- The Journal of Pediatrics
- The Journal of Clinical Endocrinology and Metabolism
- Medical Physics
- Nuclear Medicine Communications
- International Journal of Radiation Biology
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal of Lipid Research
Articles by Richard Freifelder in JoVE
Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases Pedro Brugarolas1, Mohammed Bhuiyan2, Anna Kucharski2, Richard Freifelder2 1Department of Neurology, The University of Chicago, 2Department of Radiology, The University of Chicago We demonstrate the semi-automated radiochemical synthesis of [18F]3F4AP and quality control procedures.
Other articles by Richard Freifelder on PubMed
Performance of a Brain PET Camera Based on Anger-logic Gadolinium Oxyorthosilicate Detectors Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. Aug, 2003 | Pubmed ID: 12902426 A high-sensitivity, high-resolution brain PET scanner ("G-PET") has been developed. This scanner is similar in geometry to a previous brain scanner developed at the University of Pennsylvania, the HEAD Penn-PET, but the detector technology and electronics have been improved to achieve enhanced performance.
Diagnosis and Localization of Focal Congenital Hyperinsulinism by 18F-fluorodopa PET Scan The Journal of Pediatrics. Feb, 2007 | Pubmed ID: 17236890 To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism.
Accuracy of [18F]fluorodopa Positron Emission Tomography for Diagnosing and Localizing Focal Congenital Hyperinsulinism The Journal of Clinical Endocrinology and Metabolism. Dec, 2007 | Pubmed ID: 17895314 Focal lesions in infants with congenital hyperinsulinism (HI) represent areas of adenomatosis that express a paternally derived ATP-sensitive potassium channel mutation due to embryonic loss of heterozygosity for the maternal 11p region. This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions.
Comparison of Diffuse Optical Tomography of Human Breast with Whole-body and Breast-only Positron Emission Tomography Medical Physics. Feb, 2008 | Pubmed ID: 18383664 We acquire and compare three-dimensional tomographic breast images of three females with suspicious masses using diffuse optical tomography (DOT) and positron emission tomography (PET). Co-registration of DOT and PET images was facilitated by a mutual information maximization algorithm. We also compared DOT and whole-body PET images of 14 patients with breast abnormalities. Positive correlations were found between total hemoglobin concentration and tissue scattering measured by DOT, and fluorodeoxyglucose (18F-FDG) uptake. In light of these observations, we suggest potential benefits of combining both PET and DOT for characterization of breast lesions.
Dosimetry of 11C-carfentanil, a Micro-opioid Receptor Imaging Agent Nuclear Medicine Communications. Apr, 2009 | Pubmed ID: 19242386 11C-carfentanil is a radiopharmaceutical that selectively binds the mu-opiate receptor of the central nervous system. However, its dosimetry throughout the body and other organs has never been reported in the literature. The purpose of this study was to measure the radiation dosimetry of 11C-carfentanil in healthy human volunteers. The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously.
The Radiation Response of Cells from 9L Gliosarcoma Tumours is Correlated with [F18]-EF5 Uptake International Journal of Radiation Biology. Dec, 2009 | Pubmed ID: 19995239 Tumour hypoxia affects cancer biology and therapy-resistance in both animals and humans. The purpose of this study was to determine whether EF5 ([2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide]) binding and/or radioactive drug uptake correlated with single-dose radiation response in 9L gliosarcoma tumours.
Biodistribution and Dosimetry of (18)F-EF5 in Cancer Patients with Preliminary Comparison of (18)F-EF5 Uptake Versus EF5 Binding in Human Glioblastoma European Journal of Nuclear Medicine and Molecular Imaging. Nov, 2010 | Pubmed ID: 20585774 The primary purpose of this study was to assess the biodistribution and radiation dose resulting from administration of (18)F-EF5, a lipophilic 2-nitroimidazole hypoxia marker in ten cancer patients. For three of these patients (with glioblastoma) unlabeled EF5 was additionally administered to allow the comparative assessment of (18)F-EF5 tumor uptake with EF5 binding, the latter measured in tumor biopsies by fluorescent anti-EF5 monoclonal antibodies.
A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans Journal of Lipid Research. Apr, 2017 | Pubmed ID: 28167703 Reverse cholesterol transport (RCT) is thought to be an atheroprotective function of HDL, and macrophage-specific RCT in mice is inversely associated with atherosclerosis. We developed a novel method using (3)H-cholesterol nanoparticles to selectively trace macrophage-specific RCT in vivo in humans. Use of (3)H-cholesterol nanoparticles was initially tested in mice to assess the distribution of tracer and response to interventions known to increase RCT. Thirty healthy subjects received (3)H-cholesterol nanoparticles intravenously, followed by blood and stool sample collection. Tracer counts were assessed in plasma, nonHDL, HDL, and fecal fractions. Data were analyzed by using multicompartmental modeling. Administration of (3)H-cholesterol nanoparticles preferentially labeled macrophages of the reticuloendothelial system in mice, and counts were increased in mice treated with a liver X receptor agonist or reconstituted HDL, as compared with controls. In humans, tracer disappeared from plasma rapidly after injection of nanoparticles, followed by reappearance in HDL and nonHDL fractions. Counts present as free cholesterol increased rapidly and linearly in the first 240 min after nadir; counts in cholesteryl ester increased steadily over time. Estimates of fractional transfer rates of key RCT steps were obtained. These results support the use of (3)H-cholesterol nanoparticles as a feasible approach for the measurement of macrophage RCT in vivo in humans.